Press release content from Marketers MEDIA. The AP news staff was not involved in its creation.
Dr Abbas Haider of Emergency Dental Service Decatur announced that he is now providing dental emergency services for patients in Belvedere Park, Georgia, and the surrounding neighbourhoods.
Dr Abbas Haider of Emergency Dental Service Decatur announced the launch of a new range of emergency dentistry services for patients in Belvedere Park, Georgia. Dr Haider has over 20 years of experience in cosmetic, implant, family and emergency dentistry.
More information can be found at https://www.emergencydentalservice.com/emergencydentist/decatur-ga-belvedere-plaza-dental
The newly launched dental emergency services at Emergency Dental Service Decatur aim to provide patients in Belvedere Park with prompt and efficient dental treatment.
When dental accidents happen, emergency dental care can be extremely beneficial for one’s oral and overall health. That is why Emergency Dental Service Decatur offers comprehensive emergency dentistry solutions for patients of all ages.
In addition, the dental team help those who do not have insurance or the money to pay for their emergency treatment. They have a dental emergency line of credit service and they can also offer an affordable dental plan for each patient.
The dental clinic provides comprehensive treatment for a multitude of dental issues, including partially and fully dislodged, broken or fractured teeth, object stuck between teeth, severe toothache, root canals, lost dental crown, bleeding crowns and bridges, and many more.
The team at Emergency Dental Service Decatur also service Adair Park, Chelsea Heights, Clairemont Gateway, Decatur Heights, College Heights, Downtown Decatur, and many other surrounding neighbourhoods. They are very experienced and efficient, and they always accommodate unplanned emergency care.
Dr Haider has been providing high-quality dental care to patients in Decatur, Georgia, for the past 20 years. He is dedicated to educating, empowering and helping his patients keep their smiles healthy and beautiful.
Emergency Dental Service Decatur currently has 158 Google reviews.
One review reads: “Amazing! Dr Haider was excellent! His staff was proficient and courteous. I would give them 10 stars if I could. Don’t be fooled by the Plaza. Once inside, the knowledge and the atmosphere provided allows you to feel like you’re in a Hollywood doctor’s office. Beyond pleased!”
Interested parties can find more by visiting the above-mentioned website or accessing https://www.emergencydentalservice.com/emergencydentist/tysons-va-avanti-dentistry and https://www.emergencydentalservice.com/emergencydentist/lombard-il-smile-more-dental
Servicing Adair Park, Chelsea Heights, Clairemont Gateway, Decatur Heights, College Heights, Downtown Decatur, EverGreen Forest, Glennwood Estates, Lenox Place, Midway Woods, Oakhurst, Parkwood, Ponce de Leon Heights, Ridgeland Park, Sycamore Street, Westchester Hills, Winnona Park.
Name: Abbas Haider
Email: Send Email
Organization: Emergency Dental Service Decatur
Address: 3521 Memorial Drive, Suite A, Decatur, GA 30032, United States
Release ID: 88981704
The Health 202: Emergency approval for a coronavirus vaccine could undermine efforts to keep researching it
A panel of independent experts is evaluating how the Food and Drug Administration is shepherding coronavirus vaccine development.
This type of meeting would normally only attract interest from Wall Street analysts and those closely involved with vaccine development. But today’s gathering is attracting widespread attention given the pandemic’s high stakes and lagging public trust in the vaccine development process.
The meeting, which will be live-streamed today, is widely viewed as reassurance that science, not the White House, is guiding the endeavor.
The unprecedented speed at which the vaccines are being developed has raised an ethical question.
Instead of waiting months or years to fully collect data on trial participants, developers are expected to apply to the FDA through an alternative pathway known as emergency use authorization. If an EUA is granted for a coronavirus vaccine, the vaccine could be given to certain high-risk populations to be spelled out by regulators.
The plan is to continue Phase 3 trials even while the vaccine is being distributed to select people, so researchers can get a fuller picture of how long the vaccine works and whether it causes side effects — and eventually apply for full authorization.
But continuing the trials requires maintaining a placebo group of patients. One question the panel is likely to consider today is whether to allow the placebo group to get the vaccine once it’s available.
If an EUA is approved, participants in that trial may want to know whether they received the vaccine – and if they didn’t, to get inoculated.
But vaccinating the placebo group could undermine the ability of researchers to make ongoing, longer-term comparisons that help determine the efficacy and safety of the vaccine.
There’s another challenge, too. There are currently 10 vaccine candidates in final-stage trials, according to The Washington Post’s tracker. If one gets emergency approval, patients in the other clinical trials may also want to know whether they received a placebo. If so, they also may be tempted to drop out of that trial so they could receive the approved vaccine.
“Issuance of EUA will likely slow down the trials,” said former FDA scientist Luciana Borio.
Vaccine manufacturers and other groups have raised concerns about this possibility.
The Biotechnology Innovation Organization wrote that it has an ethical obligation to inform trial participants that a vaccine may be available, saying “additional discussion is needed to determine how placebo-controlled trials can be maintained after an EUA is granted.”
“It is likely that any EUA issued for a covid-19 vaccine will have a broad impact on other covid-19 vaccines in development,” BIO wrote in comments submitted to the review panel.
Janssen Pharmaceuticals, which owns coronavirus vaccine developer Johnson & Johnson, submitted a letter outlining similar concerns.
“Once the first vaccines are licensed/authorized, this may lead willing volunteers to seek available vaccines over participating in ongoing trials,” the company wrote.
If the FDA approves use of the vaccine only for a narrow group of people, it could potentially minimize this risk. For example, if it
(Reuters) – The U.S. health regulator’s criteria for allowing emergency use of a COVID-19 vaccine and plans to monitor its safety after a regulatory go-ahead, are among the topics to be discussed at a closely watched meeting scheduled for Thursday.
Details posted on the Food and Drug Administration’s (FDA) website showed the U.S. Centers of Disease Control and Prevention has formulated plans to monitor safety and effectiveness of a vaccine even after the FDA allows for its emergency use.
The FDA panel would make recommendations at the end of the meeting, according to the agenda, but did not specify details.
The agenda also showed no specific application for a vaccine’s emergency use would be discussed at the meeting. The agency previously said it would hold multiple meetings in the future to discuss emergency use of a particular vaccine.
Pfizer Inc <PFE.N>, Moderna Inc <MRNA.O> and AstraZeneca <AZN.L> could provide early analyses of late-stage trials of their experimental vaccines this month or the next, following which regulators will consider regulatory authorization.
The companies did not immediately respond to a request for comment on whether they would be presenting at the meeting.
The FDA earlier this month told coronavirus vaccine developers it wants at least two months of safety data before authorizing emergency use, a requirement that likely pushes any U.S. vaccine availability past the Nov. 3 presidential election.
The meeting, which is open to the public for comments, is another example of steps health regulators are taking to assuage public distrust related to coronavirus vaccines, that are being developed at unprecedented speed.
There are no approved vaccines for the coronavirus, except two in Russia that are yet to finish Phase 3 clinical testing.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Mount Sinai doctors elected to National Academy of Medicine for contributions to emergency medicine and translational genetics
Brendan G. Carr, MD, MA, MS, Chair of Emergency Medicine for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, and Judy H. Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai and Director of The Charles Bronfman Institute for Personalized Medicine, have been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With their election, Mount Sinai has 25 faculty members in the NAM.
“The recognitions of Dr. Carr and Dr. Cho are well deserved for their groundbreaking contributions to emergency medicine and translational genetics,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. “Dr. Carr’s research has focused not only on improving the emergency care system for time-sensitive conditions such as trauma, stroke, cardiac arrest, and sepsis, but also on creating a more distributed and innovative approach to increasing access to acute care. Likewise, Dr. Cho is committed to improving care through personalized medicine and the understanding of each patient’s unique genes. She has enhanced genetic research, clinical implementation, and data platforms to ensure Mount Sinai remains at the forefront of genetic discoveries and implementation.”
A leading voice in emergency medicine, Dr. Carr played a central role in coordinating Mount Sinai’s response to the COVID-19 pandemic. He has dedicated his career as an emergency medicine physician and health policy researcher to seamlessly combining research, policy, and practice to advance acute care delivery. Before joining Mount Sinai in February 2020, Dr. Carr held faculty positions at the Sidney Kimmel Medical College at Thomas Jefferson University and the Perelman School of Medicine at the University of Pennsylvania.
Outside academia, Dr. Carr has worked within the U.S. Department of Health and Human Services during both the current and previous administrations to improve trauma and emergency care services at the national level. His roles have included Senior Advisor and Director of the Emergency Care Coordination Center within the Office of the Assistant Secretary for Preparedness and Response, focusing on integrating the emergency care system into the broader health care delivery system. He previously supported the Indian Health Service’s initiatives to improve emergency care delivery, and worked with the Department of Veterans Affairs and the Department of Defense to integrate military and civilian health care response during disasters and public health emergencies. Dr. Carr has advised and supported major not-for-profit foundations, the World Health Organization, and the National Academy of Medicine.
He conducts health services research that connects disciplines including epidemiology, health care policy, business, economics, and health care delivery system science. His work has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. He has published and lectured widely on systems of care for trauma, stroke, cardiac
FLANDERS, NY — Front line heroes have were honored this week as the Big Duck in Flanders was illuminated in purple to thank emergency nurses for their dedication.
Southampton Town officials gathered Wednesday to mark the Emergency Nurses Association’s celebration of Emergency Nurses Week, which takes place on October 11 through October 17.
Several nurses from a number of Suffolk County hospitals were present as the Duck was lit in purple by County Executive Steve Bellone, Southampton Town Supervisor Jay Schneiderman, Southampton Town board members Rick Martel and Tommy John Schiavoni, New York State Assemblyman Fred Thiele and Suffolk County Legislator Bridget Fleming.
Also, in honor of the nurses’ dedication, the town board awarded a proclamation to President of the Suffolk County Nurses Association Mary DaSilva.
“The Emergency Nurses Week 2020 theme does more than just show appreciation and gratitude. The theme, ‘Heart of Gold’, helps ensure that others know about emergency nurses. This week of recognition helps others to see the heart that emergency nurses bring to their hospitals and patients every day,” town officials said.
“With the challenges that we have faced in 2020 due to the horrible effects of the COVID-19 pandemic, it is more important than ever to take time out to recognize the amazing contribution to the well-being of our community that emergency nurses make,” town officials added. “These everyday heroes are there for members of our communities when things are at their worst and times are bad. They have been on the front lines of the COVID response.”
Town officials said they were proud to serve as the home of Stony Brook Southampton Hospital, as well as of the partnerships that exist with Peconic Bay Medical Center and Eastern Long Island Hospital.
“Health services on the East End of Long Island are second to none and this is in large part due to the dedicated, caring, talented professionals at our area hospitals,” officials said.
Since 1989, the Emergency Nurses Association has recognized the second Wednesday in October as Emergency Nurses Day, a day honoring emergency nurses for their commitment to patient care, town officials explained.
“In 2001, ENA expanded the celebration to devote an entire week to honoring emergency nurses, because one day is simply not enough to recognize all contributions made by emergency nurses,” officials said.
This article originally appeared on the Southampton Patch